Adamis pharmaceuticals announces nih grant funding for the treatment of alcohol use disorder

San diego, june 26, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary dmk pharmaceuticals corporation was the recipient of a grant from the national institute on alcohol abuse and alcoholism (niaaa) of the national institutes of health (nih) to support the development of a novel bifunctional small molecule for the treatment of alcohol use disorder (aud) (#r41aa030226).
ADMP Ratings Summary
ADMP Quant Ranking